Compare OWLT & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OWLT | CBIO |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | United States |
| Employees | 114 | 44 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.7M | 557.8M |
| IPO Year | N/A | N/A |
| Metric | OWLT | CBIO |
|---|---|---|
| Price | $5.43 | $19.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $17.50 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 281.4K | 242.5K |
| Earning Date | 05-07-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.89 | N/A |
| Revenue Next Year | $21.22 | $279.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.09 | $8.72 |
| 52 Week High | $16.94 | $20.58 |
| Indicator | OWLT | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.08 | 71.72 |
| Support Level | $4.19 | $10.89 |
| Resistance Level | $9.17 | $20.58 |
| Average True Range (ATR) | 0.37 | 1.83 |
| MACD | 0.28 | 0.18 |
| Stochastic Oscillator | 89.01 | 90.73 |
Owlet Inc is engaged in providing a digital parenting platform that aims to give parents real-time data and insights to help parents feel more calm and confident. Its diversified portfolio of products includes Owlet Smart Sock, the first baby monitor to track an infant's oxygen levels, heart rate, and sleep trends; the Owlet Cam, which turns any smartphone into a baby monitor with high-definition clarity; the Owlet Monitor Duo, which offers the intelligence of the Owlet Smart Sock paired with the Owlet Cam; and Owlet Dream Lab, an interactive online program designed to be a parent's guide to building healthy sleep habits for their infants.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.